"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes(Memorial Sloan Kettering Cancer Center), Andrew B. Lassman(Columbia University), Geoffrey R. Oxnard(Foundation Medicine (United States)), Jennifer Clarke(Cornell University), Mark G. Kris(Memorial Sloan Kettering Cancer Center), William Pao(Albany Medical Center Hospital), Andrei I. Holodny(Cornell University), V.A. Miller(Cornell University)
Cited by 343
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k